» Articles » PMID: 6689425

A Dose and Time Response Analysis of the Treatment of Hodgkin's Disease with MOPP Chemotherapy

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1983 Feb 1
PMID 6689425
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

A dose-response analysis of the results of MOPP chemotherapy in 132 patients with Hodgkin's disease was carried out. Complex statistical methods were utilized including 40 different dose-time variables and multivariate logistic analyses of 21 clinical variables, both simply and in stepwise regression. These covariates were not independent, and in stepwise regression analysis only B-symptoms and the mean three-cycle rate of drug delivery significantly influenced complete remission attainment. Two parameters, bone marrow involvement (negative) and lung involvement (positive), significantly influenced the duration of complete remission. Survival was influenced adversely by pleural involvement (effusion), advanced age, and B-symptoms. Analyses indicate that the dose of all three drugs (mustard, vincristine, and procarbazine), and the rate of drug delivery during the first three cycles are important in achieving maximal complete response rates, especially for patients with B-symptoms.

Citing Articles

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

OBrien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W J Clin Oncol. 2012; 31(6):676-83.

PMID: 23169518 PMC: 4979201. DOI: 10.1200/JCO.2012.46.2309.


Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma.

Vakkalanka B, Link B Adv Hematol. 2011; 2011:656013.

PMID: 21687649 PMC: 3112508. DOI: 10.1155/2011/656013.


A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Schwartz C, Constine L, Villaluna D, London W, Hutchison R, Sposto R Blood. 2009; 114(10):2051-9.

PMID: 19584400 PMC: 2744567. DOI: 10.1182/blood-2008-10-184143.


New treatments for Hodgkin's disease.

Glossmann J, Josting A, Diehl V Curr Treat Options Oncol. 2002; 3(4):283-90.

PMID: 12074765 DOI: 10.1007/s11864-002-0028-x.


Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

Garcia R, Hernandez J, Caballero M, Gonzalez M, Galende J, Del Canizo M Br J Cancer. 1993; 68(6):1227-31.

PMID: 8260377 PMC: 1968658. DOI: 10.1038/bjc.1993.509.